Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...

Femasys (NASDAQ:FEMY – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $12.00 target price ...

H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

H.C. Wainwright analyst Mike Colonnese increased the price target for Coinbase Global Inc. (NASDAQ:COIN) shares to $330, up from the previous $255, while maintaining a Buy rating on the stock. The ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...